CDEK
← All drugs Report issue

desvenlafaxine

Trade name: pristiq

Small moleculeapproved

Approved

Feb 29, 2008

Desvenlafaxine is a dual serotonin and norepinephrine reuptake inhibitor in vitro and in vivo that demonstrates good brain-to-plasma ratios. Desvenlafaxine has demonstrated antidepressant effects in preclinical studies. Pfizer is developing an oral, extended-release formulation of desvenlafaxine for the treatment of major depressive disorder. Desvenlafaxine has been registered and is available on the market for the treatment of major depressive disorder in adults. — NCATS

Clinical trial activity

97 trials · 46 clinical orgs · 19 marketing orgs

Phase 1
14
Phase 2
51
Phase 3
46
Phase 4
20

Earliest trial started Jun 23, 2003 (NCT00063206)

Timeline

2000s

  1. Jan 1, 2003

    Pfizer — Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2006

    Pfizer — Earliest Phase 1 Sponsor(trial)

  4. Feb 29, 2008

    Wyeth — Earliest FDA Approval

  5. Feb 29, 2008

    Pfizer — NDA Secondary Org

  6. Feb 29, 2008

    Wyeth — NDA Organization

2010s

  1. Mar 4, 2013

    Alembic — NDA Secondary Org

  2. Jul 10, 2013

    Osmotica Pharmaceutical — NDA Secondary Org

  3. Oct 11, 2013

    Teva — NDA Secondary Org

  4. Jan 28, 2014

    Sun Pharmaceuticals — Marketing Organization

  5. Jan 28, 2014

    Sun Pharmaceuticals — NDA Secondary Org

  6. Jun 29, 2015

    CASI Pharmaceuticals, Inc. — Marketing Organization

  7. Jun 29, 2015

    Lupin — Marketing Organization

  8. Jun 29, 2015

    Mylan — Marketing Organization

  9. Jun 29, 2015

    Alembic — Marketing Organization

  10. Jun 29, 2015

    Rubicon Research — Marketing Organization

  11. Feb 16, 2016

    West-Ward Pharmaceutical — Marketing Organization

  12. Feb 16, 2016

    Hikma — Marketing Organization

  13. May 20, 2016

    Anchen Pharmaceuticals, Inc — Marketing Organization

  14. May 20, 2016

    Bristol-Myers Squibb — Marketing Organization

  15. Jul 29, 2016

    Actavis — Marketing Organization

  16. Jul 29, 2016

    Allergan PLC (2015) — Marketing Organization

  17. Oct 11, 2017

    Zydus Discovery DMCC — Marketing Organization

  18. Oct 1, 2018

    Yichang Humanwell Pharmaceutical Co.,Ltd — Marketing Organization

  19. May 7, 2019

    Intellipharmaceutics — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedFeb 29, 2008

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O
Mol. weight
397.47 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine
  • desvenlafaxine fumarate
  • desvenlafaxine fumarate
  • desvenlafaxine fumarate
  • desvenlafaxine fumarate
  • desvenlafaxine succinate
  • desvenlafaxine succinate
  • desvenlafaxine succinate
  • desvenlafaxine succinate
  • desvenlafaxine succinate
  • dvs-233
  • dvs-233
  • dvs-233
  • o-desmethylvenlafaxine
  • o-desmethylvenlafaxine
  • o-desmethylvenlafaxine
  • odv
  • odv
  • odv
  • pristiq
  • pristiq
  • pristiq
  • pristiq
  • pristiq
  • wy-45233
  • wy-45233

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07208357N/AOct 20, 2025Capital Medical University
NCT07171320N/ASep 15, 2025Capital Medical University, Jiujiang University
NCT06426485Phase 4May 30, 2024Luye Pharma
NCT06278038N/AFeb 22, 2024Zhejiang University
NCT06270433N/AFeb 19, 2024Nanjing University
NCT06026917Phase 4Sep 25, 2023Jiao Tong University, Yantai University
NCT05970510Phase 3Jul 30, 2023Luye Pharma, Peking University
NCT05849272Phase 4Jun 1, 2023Jiao Tong University
NCT05905120Phase 1Mar 2, 2023Jiao Tong University, Yantai University
NCT05273996Phase 4Sep 28, 2021National Institute of Mental Health (NIMH), University of Connecticut
NCT04448431Phase 4Jun 18, 2020Lundbeck
NCT04364997Phase 3May 20, 2020Shijiazhuang Pharma Group (CSPC)
NCT04345471Phase 3Apr 30, 2020Mochida Pharmaceutical Company, Ltd., Pfizer
NCT03733574Phase 1Jun 19, 2018Luye Pharma
NCT03357796Phase 1Nov 27, 2017Luye Pharma
NCT02819921Phase 4May 1, 2017Korea Cancer Center Hospital, Pfizer, Seoul National University
NCT02972060Phase 2Mar 1, 2017Bayer, European Organisation for Research and Treatment of Cancer, Université catholique de Louvain
NCT02867020Phase 2Jan 1, 2017Janssen Pharmaceutica NV, Latin American Cooperative Oncology Group
NCT02988024Phase 1Dec 7, 2016Luye Pharma
NCT02859103Phase 4Nov 1, 2016University of Toronto
Showing 20 of 97 trials
Page 1 / 5

Organizations

Research & Development (46)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit615452003
WyethFor profit33042003
Luye PharmaFor profit6632014
Jiao Tong UniversityAcademic/Hospital4332013
OtsukaFor profit4422009
Capital Medical UniversityAcademic/Hospital2212025
University of British ColumbiaAcademic/Hospital2122010
University of ConnecticutAcademic/Hospital2222013
University of TorontoAcademic/Hospital2222012
Yantai UniversityAcademic/Hospital2022023
BayerFor profit1012017
BC Women's Hospital & Health CentreAcademic/Hospital1112010
Canadian Research Initiative in Substance MisuseAcademic/Hospital1112014
Centre de recherche Fernand-Seguin, Hôpital Louis-H. LafontaineAcademic/Hospital1112011
Columbia UniversityAcademic/Hospital1112012
European Organisation for Research and Treatment of CancerAcademic/Hospital1112017
GenentechFor profit1012008
Hamilton Health Sciences CorporationAcademic/Hospital1112009
Harvard UniversityAcademic/Hospital1112008
Janssen Pharmaceutica NVFor profit1012017
46 organizations
Page 1 / 3

Marketing (23)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGJul 29, 2016
AlembicFor profitNDA2Mar 4, 2013
AlembicFor profitMKTGJun 29, 2015
Allergan PLC (2015)For profitMKTGJul 29, 2016
Anchen Pharmaceuticals, IncFor profitMKTGMay 20, 2016
Bristol-Myers SquibbFor profitMKTGMay 20, 2016
CASI Pharmaceuticals, Inc.For profitMKTGJun 29, 2015
HikmaFor profitMKTGFeb 16, 2016
HikmaFor profitSYNFeb 16, 2016
IntellipharmaceuticsFor profitMKTGMay 7, 2019
LupinFor profitMKTGJun 29, 2015
MylanFor profitMKTGJun 29, 2015
MylanFor profitSYNJun 29, 2015
Osmotica PharmaceuticalFor profitNDA2Jul 10, 2013
PfizerFor profitNDA2Feb 29, 2008
Rubicon ResearchFor profitMKTGJun 29, 2015
Sun PharmaceuticalsFor profitMKTGJan 28, 2014
Sun PharmaceuticalsFor profitNDA2Jan 28, 2014
TevaFor profitNDA2Oct 11, 2013
West-Ward PharmaceuticalFor profitMKTGFeb 16, 2016
WyethFor profitNDAFeb 29, 2008
Yichang Humanwell Pharmaceutical Co.,LtdFor profitMKTGOct 1, 2018
Zydus Discovery DMCCFor profitMKTGOct 11, 2017